Suppr超能文献

糖尿病视网膜病变的筛查与管理:当前方法

Screening for and managing diabetic retinopathy: current approaches.

作者信息

Bloomgarden Zachary T

机构信息

Department of Medicine, Division of Endocrinology, Mount Sinai School of Medicine, 35 E. 85th Street, New York, NY 10028-0954, USA.

出版信息

Am J Health Syst Pharm. 2007 Sep 1;64(17 Suppl 12):S8-14. doi: 10.2146/ajhp070331.

Abstract

PURPOSE

The anatomy of the eye and the pathogenesis, clinical features, and prevalence of vision impairment from diabetic retinopathy are described. Screening and risk factors for and treatment of diabetic retinopathy also are addressed.

SUMMARY

The macula and fovea play a critical role in vision. Several interrelated biochemical pathways involving aldose reductase, advanced glycation end products, and protein kinase C link chronic hyperglycemia with retinal capillary endothelial cell damage and dysfunction in patients with diabetic retinopathy. Vision loss and blindness from diabetic retinopathy usually are the result of vascular leakage or ischemia. Screening for retinopathy should be performed within three to five years after the onset of type 1 diabetes and shortly after the diagnosis of type 2 disease, with annual follow-up examinations in both types of diabetes. In patients with diabetic retinopathy, severe vision impairment is less common and less readily corrected than mild vision impairment, and vision impairment is more common and less readily corrected in elderly patients with diabetes than in younger diabetics. Modifiable risk factors for diabetic retinopathy include A1C level, hypertension, cigarette smoking, and dyslipidemia. Tight control of blood glucose concentrations and blood pressure can reduce the risk for and progression of diabetic retinopathy. Aspirin therapy and smoking cessation also are recommended. Dyslipidemia in patients with diabetes is associated with retinopathy progression and vision loss. Treatment of dyslipidemia provides cardiovascular benefits in patients with diabetes, but whether it provides vision benefits remains to be determined. Laser photocoagulation therapy reduces the risk of vision loss in patients with diabetic macular edema, severe nonproliferative diabetic retinopathy, or proliferative diabetic retinopathy. Intraocular surgery may be used for patients with vitreous hemorrhage and retinal detachment of the macula.

CONCLUSION

Therapeutic approaches used for patients with or at risk for diabetic retinopathy include drug therapy to reduce modifiable risk factors, laser photocoagulation, and intraocular surgery. Screening plays an important role in early detection and intervention to prevent the progression of diabetic retinopathy.

摘要

目的

描述眼睛的解剖结构以及糖尿病性视网膜病变导致视力损害的发病机制、临床特征和患病率。还讨论了糖尿病性视网膜病变的筛查、危险因素及治疗方法。

总结

黄斑和中央凹在视力中起关键作用。在糖尿病性视网膜病变患者中,涉及醛糖还原酶、晚期糖基化终产物和蛋白激酶C的几个相互关联的生化途径将慢性高血糖与视网膜毛细血管内皮细胞损伤及功能障碍联系起来。糖尿病性视网膜病变导致的视力丧失和失明通常是血管渗漏或缺血的结果。1型糖尿病发病后三至五年内以及2型糖尿病确诊后应立即进行视网膜病变筛查,两种类型的糖尿病均需每年进行随访检查。在糖尿病性视网膜病变患者中,严重视力损害比轻度视力损害更少见且更难矫正,老年糖尿病患者的视力损害比年轻糖尿病患者更常见且更难矫正。糖尿病性视网膜病变的可改变危险因素包括糖化血红蛋白水平、高血压、吸烟和血脂异常。严格控制血糖浓度和血压可降低糖尿病性视网膜病变的风险及进展。还建议进行阿司匹林治疗和戒烟。糖尿病患者的血脂异常与视网膜病变进展和视力丧失有关。治疗血脂异常对糖尿病患者有心血管益处,但对视力是否有益仍有待确定。激光光凝治疗可降低糖尿病性黄斑水肿、重度非增殖性糖尿病性视网膜病变或增殖性糖尿病性视网膜病变患者的视力丧失风险。玻璃体出血和黄斑视网膜脱离患者可采用眼内手术。

结论

用于糖尿病性视网膜病变患者或有患糖尿病性视网膜病变风险的患者的治疗方法包括药物治疗以降低可改变的危险因素、激光光凝和眼内手术。筛查在早期发现和干预以预防糖尿病性视网膜病变进展中起重要作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验